Abstract
Treatment of paroxysmal nocturnal hemoglobinuria (PNH) includes C5 complement inhibitors ravulizumab and eculizumab. Ravulizumab dosing varies by weight and includes a loading dose, followed by maintenance doses given every 8 weeks via intravenous infusion. This study investigated real-world dosing patterns of eculizumab-naive and eculizumab-experienced patients with PNH receiving ravulizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
